Domine Gomez, Manuel manuel.domine@uam.es
Actividades
- Artículos 38
- Libros 1
- Capítulos de libro 0
- Congresos 0
- Documentos de trabajo 0
- Informes técnicos 0
- Proyectos de investigación 0
- Tesis dirigidas 0
- Patentes o licencias de software 0
Galectin-1, a novel promising target for outcome prediction and treatment in SCLC
- Corral JM
- Puerto-Nevado LD
- Cedeño M
- Río-Vilariño A
- Mahillo-Fernández I
- Galeano C
- Baños N
- García-Foncillas J
- Dómine M
- Cebrián A
Biomedicine & Pharmacotherapy (p. 113987-113987) - 1/12/2022
- ISSN 07533322
- iMarina
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
- Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S, ETOP 10-16 BOOSTER Collaborators
Annals Of Oncology (p. 181-192) - 1/2/2022
10.1016/j.annonc.2021.11.010 Ver en origen
- ISSN 09237534
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
- Wu, YL
- John, T
- Grohe, C
- Majem, M
- Goldman, JW
- Kim, SW
- Kato, T
- Laktionov, K
- Vu, HV
- Wang, ZJ
- Lu, S
- Lee, KY
- Akewanlop, C
- Yu, CJ
- de Marinis, F
- Bonanno, L
- Domine, M
- Shepherd, FA
- Zeng, LM
- Atasoy, A
- Herbst, RS
- Tsuboi, M
Journal Of Thoracic Oncology (p. 423-433) - 1/3/2022
10.1016/j.jtho.2021.10.014 Ver en origen
- ISSN 15560864
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
- Provencio M
- Serna-Blasco R
- Nadal E
- Insa A
- García-Campelo MR
- Casal Rubio J
- Dómine M
- Majem M
- Rodríguez-Abreu D
- Martínez-Martí A
- De Castro Carpeño J
- Cobo M
- López Vivanco G
- Del Barco E
- Bernabé Caro R
- Viñolas N
- Barneto Aranda I
- Viteri S
- Pereira E
- Royuela A
- Calvo V
- Martín-López J
- García-García F
- Casarrubios M
- Franco F
- Sánchez-Herrero E
- Massuti B
- Cruz-Bermúdez A
- Romero A
Journal Of Clinical Oncology (p. 2924-2933) - 1/5/2022
10.1200/jco.21.02660 Ver en origen
- ISSN 0732183X
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- Arriola, E
- Gonzalez-Cao, M
- Domine, M
- De Castro, J
- Cobo, M
- Bernabe, R
- Navarro, A
- Sullivan, I
- Trigo, JM
- Mosquera, J
- Crama, L
- Isla, D
Oncology And Therapy (p. 167-184) - 1/6/2022
10.1007/s40487-021-00182-0 Ver en origen
- ISSN 23661089
Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non-small cell lung cancer.
- Ferrer, L
- Nadal, E
- Guidel, F
- Insa, A
- Menu, P
- Casal, J
- Domine, M
- Massuti, B
- Majem, M
- Martinez-Marti, A
- Campelo, RG
- Carpeon, JD
- Cobo, M
- Vivanco, GL
- del Barco, E
- Bernabe, R
- Vinolas, N
- Barneto, I
- Colin, T
- Provencio-Pulla, M
Journal Of Clinical Oncology - 1/6/2022
- ISSN 0732183X
- iMarina
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
- Majem, M
- Goldman, JW
- John, T
- Grohe, C
- Laktionov, K
- Kim, SW
- Kato, T
- Vu, HV
- Lu, S
- Li, SQ
- Lee, KY
- Akewanlop, C
- Yu, CJ
- de Marinis, F
- Bonanno, L
- Domine, M
- Shepherd, FA
- Atagi, S
- Zeng, LM
- Kulkarni, D
- Medic, N
- Tsuboi, M
- Herbst, RS
- Wu, YL
Clinical Cancer Research (p. 2286-2296) - 1/6/2022
10.1158/1078-0432.ccr-21-3530 Ver en origen
- ISSN 15573265
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
- Serna-Blasco R
- Sánchez-Herrero E
- Robado de Lope L
- Sanz-Moreno S
- Rodríguez-Festa A
- Ares-Trotta D
- Cruz-Bermúdez A
- Franco F
- Sánchez-Hernández A
- Campayo MdJ
- García-Girón C
- Dómine M
- Blasco A
- Sánchez JM
- Oramas J
- Bosch-Barrera J
- Sala MA
- Sereno M
- Romero A
- Provencio M
Cancers - 1/9/2022
10.3390/cancers14184446 Ver en origen
- ISSN 20726694
Multidisciplinary Thoracic Tumors Board Survey in Spain
- Massuti, B
- Nadal, E
- Camps, C
- Carcereny, E
- Cobo, M
- Domine, M
- Garcia-Campelo, MR
- Gonzalez-Larriba, JL
- Guirado, M
- Hernando-Trancho, F
- Rodriguez-Abreu, D
- Sanchez, A
- Sullivan, I
- Provencio, M
Journal Of Thoracic Oncology (p. S107-S107) - 1/9/2022
- ISSN 15560864
- iMarina
First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
- Provencio-pulla, M
- Ortega, AL
- Coves, J
- Franco, F
- Marse, R
- Domine, M
- Guirado, M
- Carcereny, E
- Fernandez, N
- Martinez, E
- Blanco, R
- Leon, L
- Sanchez, JM
- Sullivan, I
- Cobo, M
- Sanchez, A
- Massuti, B
Journal Of Thoracic Oncology (p. S123-S124) - 1/9/2022
- ISSN 15560864
- iMarina
Este/a investigador/a no tiene capítulos de libro.
Este/a investigador/a no tiene congresos.
Este/a investigador/a no tiene documentos de trabajo.
Este/a investigador/a no tiene informes técnicos.
Este/a investigador/a no tiene proyectos de investigación.
Este/a investigador/a no tiene tesis dirigidas.
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Scopus Author ID
-
Dialnet id